<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255602</url>
  </required_header>
  <id_info>
    <org_study_id>HP2020125</org_study_id>
    <nct_id>NCT04255602</nct_id>
  </id_info>
  <brief_title>A Randomized Non-inferiority Study of Low-dose and Standard-dose Ticagrelor After Intervention for Acute Coronary Syndrome</brief_title>
  <acronym>TIGER</acronym>
  <official_title>A Randomized Non-inferiority Study of Low-dose and Standard-dose Ticagrelor After Intervention for Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Tong Ren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Tong Ren Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to
      prevent major adverse cardiovascular and cerebrovascular events in one years after
      drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus
      100mg Aspirin
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of major adverse cardiovascular and cerebrovascular events(MACCES)</measure>
    <time_frame>Stent implantation to 12 months</time_frame>
    <description>death from coronary vascular causes,non-fatal myocardial infarction,stent thrombosis,coronary revascularization and stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of PLATO major bleeding event</measure>
    <time_frame>Stent implantation to 12 months</time_frame>
    <description>fatal bleeding, intracranial bleeding,intrapericardial bleeding with cardiac tamponade,hypovolemic shock or severe hypotension due to bleeding and requiring pressures or surgery, a decline in the hemoglobin level of 5.0 g per deciliter or more, or the need for transfusion of at least.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PLATO defined any bleeding events</measure>
    <time_frame>Stent implantation to 12 months</time_frame>
    <description>minor bleeding or minimal bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2120</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Coronary Stent Implantation</condition>
  <arm_group>
    <arm_group_label>low dose ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a month,subjects will be treated with ticagrelor 60mg twice daily and aspirin 100mg once daily for eleven months since drug eluting stent implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard dose ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will be treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a year since drug eluting stent implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 60mg</intervention_name>
    <description>Ticagrelor 60mg plus Aspirin 100mg for experimental group</description>
    <arm_group_label>low dose ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg</intervention_name>
    <description>Ticagrelor 90mg plus Aspirin 100mg for active comparator group</description>
    <arm_group_label>standard dose ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be at least 18 years of age

          2. Patients should have undergone successful percutaneous coronary intervention with
             drug-eluting stent for acute coronary syndrome

          3. Subject understand the study requirements and the treatment procedures and provided
             informed consent before the procedure

        Exclusion Criteria:

          1. Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study

          2. Active bleeding

          3. Known hypersensitivity or contraindication to study medications

          4. Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study

          5. Non-cardiac co-morbid conditions are present with life expectancy &lt;2 year or that may
             result in protocol non-compliance (per site investigator's medical judgment).

          6. Subjects with Cerebral hemorrhage history

          7. Subjects with stroke history in half a year

          8. subjects with malignant tumor

          9. subjects with whom oral anticoagulants are needed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Hou, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tongren hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Hou, Doctor</last_name>
    <phone>13564868096</phone>
    <email>Dr_houlei@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junbo Ge, Doctor</last_name>
    <email>Ge.junbo@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The sixth people's hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zhibing wang, doctor</last_name>
    </contact>
    <investigator>
      <last_name>zhibing wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taishan people's hospital</name>
      <address>
        <city>Taishan</city>
        <state>Guangdong</state>
        <zip>529200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yan Chen, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>yan chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The third people's hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangshu</state>
        <zip>221005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yaojun zhang, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>yaojun zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>zhangshan hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junbo Ge, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Junbo Ge, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>shanghai Tongren hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Hou, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Lei Hou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caohui Qiu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanan Peng, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minhang hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Hu, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Wei Hu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

